BioCryst Pharmaceuticals stock gains 0.92 percent as earnings beat estimates

Published on 09/23/2026 at 00:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioCryst Pharmaceuticals stock closed at USD 8.76 on September 22, 2026, up 0.92 percent. Second-quarter EPS reached USD 0.30.

BCRX, US09058V1035, Illustration mit AI erstellt.

BioCryst Pharmaceuticals, Inc. (ISIN US09058V1035) closed at USD 8.76 on Nasdaq on September 22, 2026, gaining 0.92 percent from the prior close. The move leaves the stock 21.9 percent below its 52-week high of USD 11.22 and USD 2.76 above its low of USD 6.00.

Earnings beat the estimate

BioCryst reported second-quarter 2026 earnings of USD 0.30 per share, exceeding the consensus estimate of USD 0.15 by USD 0.15, according to MarketBeat on September 22, 2026. The comparison is material because the reported EPS was twice the cited consensus estimate.

The same September 22, 2026 report states that revenue increased 33.6 percent year over year. That combination of revenue growth and an earnings beat gives the market a measurable operating signal, even though the stock remains below its yearly peak.

ORLADEYO drives the profile

BioCryst's primary commercial product is ORLADEYO, an oral once-daily treatment for preventing hereditary angioedema attacks in adults and pediatric patients aged 12 and older, as described by MarketBeat on September 22, 2026. The product focus makes prescription revenue and sustained year-over-year growth central metrics for assessing the company.

MarketBeat also listed a consensus price target of USD 20.40 and a Moderate Buy consensus rating on September 22, 2026. The target stands 132.9 percent above the September 22 closing price, a wide gap that reflects the difference between current market valuation and published expectations rather than a guaranteed return.

Stock remains below its yearly high

Nasdaq trading on September 22, 2026 ended with 3.46 million shares changing hands, while market capitalization stood at USD 2.24 billion. BioCryst had risen 12.3 percent since January 1, 2026, when the stock was reported at USD 7.80.

For investors, the key tension is visible in the numbers: the company delivered second-quarter EPS of USD 0.30 against USD 0.15 consensus, while the share price remained below USD 9.00 and below the USD 11.22 52-week high. Future results will determine whether the reported growth can narrow that valuation gap.